binx health today announced the submission of an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for the first CLIA-waived CRISPR-based point-of-care (POC) test for COVID-19. binx io is already the first CLIA-waived platform for the molecular detection of chlamydia and gonorrhea in about 30 minutes. binx has now adapted the single-use cartridge for analysis

Atlas Genetics, a rapid, near-patient and point-­of-­care (POC) testing company, today announced that it has appointed Stanley Lapidus to the role of independent board member on its Board of Directors. Lapidus has more than 30 years’ experience in the medical diagnostics industry as a founder, CEO and board member at companies that have dramatically impacted the diagnostics landscape, including hi

Atlas Genetics, a pioneer in near-patient testing solutions, has been renamed binx health, and has aligned with additional healthcare pioneers as it redefines new categories of convenient testing where people live, work and shop. “Reaching tens of millions of people globally with convenient solutions for routine care, requires evidence-based tools in digital health and rapid-PCR desktop instrument

Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded an SBRI grant from Innovate UK to assist in the development of an ultra-rapid POC multiplex STI test measuring the four most commonly occurring pathogens (Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis and Mycoplasma

binx health, the pioneer in anywhere, anytime testing for women’s health, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its first-of-kind, highly sensitive and specific, molecular point-of-care (POC) diagnostic testing platform, the binx io®. The binx io platform is a rapid, qualitative, fully-automated test, designed to be easy t

Wellfleet Insurance has teamed up with binx health to offer college clients access to easy at-home/in-dorm sample collection for COVID-19 testing using binx’s enterprise solutions for population health screening. ‘binx boxes’ are showing up in dorm rooms of thousands of students on Wellfleet’s college client campuses, offering school officials a quick, easy way to test a campus population, with ov

binx health ltd. today announced the first of its kind private offering for at-home sample collection and contactless courier service for laboratory COVID-19 testing for all residents in the United Kingdom. Leveraging the binx digital platform and the Company’s decade of experience developing evidence-based, near-patient infectious disease diagnostics, binx and Polar Speed, a specialist UPS Health

binx health, a first-of-kind population health technology company, announced today that it received an important amendment to its COVID-19 Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), this time for centralized specimen collection kit distribution and retrieval by large partners. The FDA noted in binx’s amended EUA that the binx sample collection kit supports

binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study and shop, today announced the closing of a Series E financing of $104 million. The financing was led by OrbiMed, and included other new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global, along with

binx health, a population health technology company that provides convenient healthcare solutions, announced today that its FDA emergency-use authorized at-home nasal swab COVID-19 Sample Collection Kit is now available for delivery to Amazon Business customers across the United States. binx health is a proven leader in accurate, convenient testing and is aiming to redefine population health by ma

Today, the U.S. Food and Drug Administration announced it is allowing the use of the Binx Health IO CT/NG Assay at point-of-care settings, such as in physician offices, community-based clinics, urgent care settings, outpatient health care facilities and other patient care settings, operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation. This action

Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded a two year Innovate UK phase II contract to expand the Sexually Transmitted Infection (STI) test menu for the io® rapid diagnostic platform and support its adoption into UK sexual health clinics. Valued at approximately £2m, this contract will bring together Atlas Geneti

Atlas Genetics Ltd., the ultra-­rapid, point-­of-­care (POC) testing company for women’s and family health, today announced that Jeffrey R. Luber has been appointed Chief Executive Officer effective 1 October 2017. Dr John Clarkson, current founding CEO, will become Executive Chairman and current chairman, Neil Butler, will remain with the Company as a non-­executive director of the Board. Mr. Lub

binx health, a population health technology company that provides convenient healthcare solutions, announced today that the US Food and Drug Administration (FDA) has granted Clinical Laboratory Improvement Amendments (CLIA) waiver for the binx io system, a first-of-its kind molecular point-of-care testing platform capable of delivering central laboratory quality results in about 30 minutes, for th

Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech. Development of the Atlas Genetics io® system has been completed with the successful CE marking of the Chlamydia trachomatis (CT) test announced in Feb

binx health, the pioneer in anywhere, anytime testing for women’s health, today announced that Jeffrey Luber, president and CEO is scheduled to present on Thursday, November 21, 2019 at 11:00 a.m. ET at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York City. Management will be available for one-on-one meetings throughout the conference. The presentation will be webcast live

binx health, the pioneer in anywhere, anytime testing for women’s health, today announced the first real-world use of the binx io platform, delivering same-visit diagnosis and treatment for chlamydia (CT) and gonorrhea (NG)—the two most tested-for sexually transmitted infections (STIs) globally. The World Health Organization (WHO) has previously indicated that the lack of reliable, low-cost, point

binx health today announced the publication of its pivotal clinical study for its rapid molecular point-of-care platform, the binx io, in The Journal of the American Medical Association (JAMA) Network Open. The study shows that the binx io provides accurate results in about 30 minutes, enabling single visit test and treatment for chlamydia (CT) and gonorrhea (NG), two of the most tested-for sexual

A first-of-kind FDA-cleared infectious disease platform, the binx io provides results in about thirty minutes, which enables diagnosis and treatment of chlamydia (CT) and gonorrhea (NG) to take place in a single visit. The binx io’s test performance has been demonstrated to be on par with central-laboratory testing. Today, about thirty-five million CT/NG tests are processed at central laboratories

binx health today announced the launch of its pre-order program for the world’s first FDA-cleared, rapid molecular point-of-care instrument, which provides diagnosis in about 30 minutes to enable single visit test and treatment for chlamydia (CT) and gonorrhea (NG) in women. CT and NG are two of the most tested-for sexually transmitted infections (STIs) globally. binx received FDA 510(k) clearance

Mr. Parikh has held various leadership positions within Amazon, including as an early catalyst behind its entry into healthcare. Parikh was also instrumental in the company’s recent acquisition of PillPack. His roles at Amazon have included Global Leader, Business Development & Strategy (Consumables & Consumer Healthcare) and General Manager, CPG, Consumer Healthcare, and Consumer Healthcare Innov

binx health is excited to announce it will provide university-wide COVID-19 testing for the New York Film Academy (NYFA), among the most highly regarded visual and performing arts colleges in the world. The binx platform will enable at-home, in-dorm and on campus specimen collection, providing healthcare convenience for NYFA students, faculty and staff at campuses in New York, Los Angeles and Miam

Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the STI Point-Of-Care (POC) molecular diagnostics company, today notes the major issue of antibiotic resistance for Sexually Transmitted Infections (STIs), as highlighted in the UK Government commissioned anti-microbial resistance report, chaired by Jim O’Neill – ‘Tackling Drug-Resistant Infections Globally’ and recently referenced on the BBC

binx health was featured in Fortune Magazine highlighting the io platform as not only the first and fastest FDA-cleared molecular point-of-care diagnostic for the detection of chlamydia and gonorrhea, but also for its potential to be a “breakthrough” in efforts to prevent and control STIs. UCLA epidemiologist Jeffrey Klausner highlights the need for “new tools and strategies” to combat the growing

binx health, a leader in infectious disease testing solutions, announced that it has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) in one of the largest markets for infectious disease testing. Today, the Company announces FDA 510(k) clearance to market its sensitive and specific, molecular point-of-care testing platform, the binx io, for the detection of chlam

Sherlock Biosciences and binx health today announced the companies have entered into a strategic partnership to develop the world’s first rapid, point-of-care diagnostic test for COVID-19 leveraging CRISPR technology. The organizations will combine the binx io diagnostic platform with SHERLOCK™ CRISPR technology to create a test that is robust and simple to use. This unique solution is designed to

binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today the appointment of Jeff Grosklags, an accomplished industry leader and UnitedHealth Group’s Optum Rx Chief Financial Officer (CFO) to its Board of Directors. For the past 16 years, Grosklags has worked in a financia

binx health, through an expanded agreement with student health insurer Wellfleet, will provide college students nationwide access to sexually transmitted infection (STI) testing. The agreement will enable students from all colleges and universities offering student health insurance from Wellfleet, a Berkshire Hathaway company and one of the nation’s largest student health insurance carriers, acces

binx health , a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today the appointment of Todd Bennett as Chief Commercial Officer (CCO). Bennett is an accomplished industry veteran, having held multiple executive leadership roles at several high-growth companies including Luminex, Imm

Ernst & Young LLP (EY US) today announced that Jeffrey Luber, Chief Executive Officer of binx health, was named an Entrepreneur Of The Year® 2022 New England Award winner. Entrepreneur Of The Year® is one of the preeminent competitive business awards for entrepreneurs and leaders of high-growth companies who think big to succeed. An independent panel of judges selected Jeffrey Luber based on his e

binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced that the states of North Carolina and Maryland have awarded the company with contracts to provide access to the Company’s FDA emergency-use-authorized , at-home, lower nasal swab COVID-19 sample collection kits for molecul

binx health, a healthcare technology and diagnostics company is pleased to announce its selection as a finalist in the Medical Design Excellence Awards 2022. The Medical Design Excellence Awards (MDEA) is the premier awards program for the medtech industry with a mission to recognize significant achievements in medical product design and engineering that improve the quality of healthcare delivery

Ernst & Young LLP (EY US) announced that Jeff Luber, Chief Executive Officer of binx health, has been named an Entrepreneur Of The Year® 2022 New England Award finalist. Entrepreneur Of The Year is one of the preeminent competitive business awards for entrepreneurs and leaders of high-growth companies who think big to succeed. Luber was selected by a panel of independent judges according to the fo

binx health, a healthcare technology and diagnostics company, announced today the appointment of Jack Crowley as Chief Financial Officer (CFO). Crowley brings deep industry expertise in life sciences and demonstrated results in successful initial and secondary public offerings, capital structure enhancements, analyst collaboration, and investor relations. “We are thrilled to welcome Jack to our l

Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, today announced the appointment of industry veteran Marc Jones as Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”). In this dual role, Jones will lead Atlas Genetics’ finance and operations functions, as well as new channel development, and he will again partner with Jeffrey Luber, President and Chief

binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, has partnered with student health insurer Wellfleet to broaden access to human papillomavirus (HPV) testing through convenient, at-home sample collection. The companies believe this joint initiative will encourage more Americans to get tested for HPV, in the settings and at the times most con

binx health, a healthcare technology and diagnostics company that makes routine testing convenient, and the North Dakota Department of Health (NDDoH) are working together to combat the spread and support the treatment of sexually transmitted infections (STIs). Through this collaboration, North Dakota residents ages 14 and older can discreetly obtain an at-home sample collection kit at no cost fro

New placement program for the binx io, the first and only male/female FDA-cleared, CLIA-waived point-of-care instrument for chlamydia (CT) and gonorrhea (NG), offers CLIA-waived facilities the opportunity to deliver critical CT/NG results in about 30 minutes versus days through centralized lab testing BOSTON, November 1, 2022 – binx health, a healthcare technology and women’s health company focu

binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a strategic agreement with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationally through their Group Purchasing Organization (GPO). Under the agreement, binx will offer its FDA-cleared, CLIA-waived point-of-care test for chlamydia (CT) and

In a first of its kind partnership, the Alabama Department of Public Health (ADPH) and binx health, a healthcare technology and diagnostics company, enables access to routine remote sample collection for sexually transmitted infections (STIs) and subsequent treatment for Alabama residents. The program consists of STI/HIV self-collection kits made available to order online through the binx *everywh

Sassy Little Box Program Powered by binx everywhere Digital Platform & Logistics Makes At-Home Self-Collection Kits Available Through Community Partners BOSTON, MA and BIRMINGHAM, AL (March 1, 2023) Birmingham AIDS Outreach (BAO), Alabama’s leading advocacy organization for people living with HIV/AIDS, and binx health, a healthcare technology and diagnostics company focused on making routine tes

BOSTON--(BUSINESS WIRE)--binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced that Jeff Luber, Chief Executive Officer of binx health, will present a company overview presentation at William Blair’s Innovator Series: Life Science Tools and Diagnostics on December 13th, 2022. The presentation will be followed by a Q&A session led

BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) -- February 23, 2023 (GLOBENEWSWIRE) – binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, announced today that Jeff Luber, Chief Executive Officer, will present at the BioCapital Europe 2023, a life sciences investment conference taking place on March 9, 2023, in Amsterdam, the Netherlands. The presentat